Altimmune announced positive topline results from its RECLAIM Phase 2 trial for pemvidutide in alcohol use disorder (AUD), meeting its primary endpoint with statistically significant reductions in heavy drinking days. The drug also demonstrated significant improvements in secondary endpoints and a favorable tolerability profile, leading to a premarket stock surge.
Altimmune reported highly encouraging Phase 2 trial results for pemvidutide in treating alcohol use disorder, showing statistically significant reductions in heavy drinking days and other key metrics. This positive data is a major catalyst for Altimmune, validating its lead drug candidate and potentially accelerating its path to market. The premarket stock surge indicates immediate positive investor reaction, and if further trials are successful, it could position Altimmune as a leader in the AUD treatment space, offering a significant long-term opportunity. The next step involves discussions with the FDA, which will be crucial for the drug's regulatory pathway.